SG Pharma Solutions
SG PHARMASOLUTIONS
SG Pharma Solutions
SG PHARMASOLUTIONS

Core Technical Consultancy

Extractables & Leachables (E&L) Consultancy

Strategic study design, non-target screening support, VOC/SVOC/NVOC evaluation, independent data review, and toxicological safety assessment tailored to your specific material and application.

Pharmaceutical analytical laboratory LC-MS instrumentation for E&L testing
Technical Overview

Material-Specific, Risk-Based E&L Support

Extractables and Leachables (E&L) evaluations are essential for ensuring patient safety and regulatory compliance across pharmaceutical packaging, drug delivery devices, and bioprocessing systems.

At SG Pharma Solutions, we emphasize that there is no one-size-fits-all testing workflow. The appropriate analytical and toxicological strategy depends directly on the constituent material, clinical route of administration, daily patient dose, contact duration, and temperature conditions.

We manage the critical technical thinking: evaluating materials, defining the Analytical Evaluation Threshold (AET), establishing study protocols, coordinating physical testing with vetted partner laboratories, critically reviewing chromatographic data, and conducting rigorous toxicological safety evaluations.

Connected Capability

Nitrosamines Risk Assessment & Technical Support

Evaluating nitrosamine formation risks from elastomeric closures, processing aids, and API synthetic routes.

Explore Nitrosamines →

Primary Applications

  • Container Closure Systems (CCS) — Vials, Stoppers, Blisters
  • Single-Use Systems (SUS) & Bioprocessing Assemblies
  • Drug Delivery Devices (Prefilled Syringes, Inhalers, Autoinjectors)
  • Ophthalmic & Parenteral Packaging
  • Transdermal & Topical Delivery Systems
  • Medical Device Fluid Path Components
Full Lifecycle Support

Comprehensive E&L Technical Capabilities

From study conception to health authority review, we provide objective technical oversight and data interpretation.

01

Study Strategy & Analytical Planning

Evaluating dosage form risks, route of administration, clinical contact duration, and regulatory expectations to determine an appropriate, material-specific testing strategy.

02

Study Design & Protocol Support

Formulating tailored extraction protocols, extraction solvents (polar, mid-polar, non-polar), simulation conditions, and testing milestones per USP <1663>/<1664> and PQRI.

03

Extractables & Leachables Assessment

Comprehensive assessment of container closure systems, single-use bioprocessing components, elastomeric seals, and drug delivery devices.

04

VOC, SVOC & NVOC Evaluation

Structured analytical evaluation covering volatile organic compounds (Headspace-GC-MS), semi-volatiles (GC-MS), non-volatiles (LC-HRMS), and elemental impurities (ICP-MS).

05

Unknown Compound Identification

Non-target screening support utilizing high-resolution mass spectrometry (LC-HRMS / GC-MS) spectral libraries, fragmentation patterns, and degradation chemistry.

06

Analytical Data Review & Interpretation

Independent, high-level technical scrutiny of raw chromatograms, mass spectra, blank subtractions, and integration parameters from testing laboratories.

07

Laboratory Coordination

Evaluating laboratory capabilities, selecting suitable testing partners, coordinating sample shipments, and monitoring study timelines.

08

Toxicological & Risk Assessment

Derivation of Permitted Daily Exposure (PDE), Threshold of Toxicological Concern (TTC), and Margin of Safety (MOS) per ICH M7, ICH Q3C/D, and ISO 10993-17.

09

Technical Reporting & Regulatory Documentation

Authoring comprehensive, submission-ready E&L safety reports, CTD Module 3 technical summaries, and responding to health authority deficiency inquiries.

Analytical Methodologies

Coordinated Analytical Techniques

Headspace GC-MSTarget: Volatile Organic Compounds (VOCs) and residual solvents
Direct Injection GC-MSTarget: Semi-Volatile Organic Compounds (SVOCs) such as plasticizers and antioxidants
LC-MS / LC-HRMS (Orbitrap / Q-TOF)Target: Non-Volatile Organic Compounds (NVOCs), oligomers, slip agents, and degradation products
ICP-MS / ICP-OESTarget: Trace elemental impurities and heavy metal catalysts per ICH Q3D
Ion Chromatography (IC)Target: Anions, cations, and inorganic leachables
Regulatory Standards

Guiding Regulatory Frameworks

Our technical consultancy aligns study protocols and documentation with major compendial and global regulatory guidelines:

  • USP <1663> & <1664>: Assessment of Extractables and Leachables
  • PQRI Recommendations: Parenteral, Ophthalmic (PODP) and Inhalation (OINDP)
  • ICH Q3D & ICH M7: Elemental Impurities and Mutagenic DNA-reactive impurities
  • ISO 10993-18 & 10993-17: Medical device chemical characterization and toxicological risk limits
Important Note: SG Pharma Solutions acts as a technical consultancy and study coordinator. Physical laboratory testing is carried out through qualified partner laboratories.